Nuvation Bio
NUVB
154 hedge funds and large institutions have $429M invested in Nuvation Bio in 2024 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 61 increasing their positions, 36 reducing their positions, and 18 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 36
39% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 18
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
4% more funds holding
Funds holding: 148 → 154 (+6)
4% less capital invested
Capital invested by funds: $447M → $429M (-$18.4M)
5.86% less ownership
Funds ownership: 61.92% → 56.07% (-5.9%)
99% less call options, than puts
Call options by funds: $7K | Put options by funds: $540K
Top Buyers
| 1 |
DC
Decheng Capital
Menlo Park,
California
|
+$58M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$35.8M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$3.72M |
| 4 |
Millennium Management
New York
|
+$2.84M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.32M |
Top Sellers
| 1 |
AIC
AWM Investment Company
New York
|
-$3.94M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$3.74M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.91M |
| 4 |
BC
BIT Capital
Berlin,
Germany
|
-$1.62M |
| 5 |
Barclays
London,
United Kingdom
|
-$1.02M |
NUVB Hedge Fund Activity: Q3 2024 in Review
154 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q3 2024, worth a combined $429M — down 4.1% from $447M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new NUVB positions and 18 closed out — a net gain of 7 holders — while 61 added to existing stakes and 36 trimmed.
The largest buyer was Decheng Capital, adding an estimated $58M. The largest seller was AWM Investment Company, exiting entirely with an estimated $3.94M sold.
- 154 institutional investors held Nuvation Bio (NUVB) as of Q3 2024, up from 148 in Q2 2024.
- Funds reported $429M of Nuvation Bio stock for Q3 2024, down 4.1% quarter-over-quarter.
- 25 funds opened new Nuvation Bio positions in Q3 2024 and 18 closed out, a net change of +7 holders.
- The largest Nuvation Bio buyer in Q3 2024 was Decheng Capital, an estimated $58M added.
- The largest Nuvation Bio seller in Q3 2024 was AWM Investment Company, an estimated $3.94M sold.
Based on aggregated 13F filings for Q3 2024.